Consolidated Lithium Metals Signs Term Sheet with Linear Minerals to Acquire the Augustus Lithium Project and Additional Lithium Claims in the Abitibi and James Bay Regions of Québec

Globe Newswire — Mon, 08 Jun 2026 22:30:00 +0000

TORONTO, June 08, 2026 (GLOBE NEWSWIRE) -- Consolidated Lithium Metals Inc. (TSXV:CLM, FRA: Z36, OTCQB:JORFF) ("CLM" or the "Company") is pleased to announce that it has entered into a term sheet ("Term Sheet") dated June 4, 2026, with Linear Minerals Corp. ("LM"), pursuant to which (subject to completion of several conditions precedent) the Company intends to acquire a 100% undivided interest in the Augustus Lithium Project and additional adjacent LM claims, located in the Abitibi and James Bay regions of Québec (the "Project") (the "Proposed Transaction").

Proposed Transaction Summary

Pursuant to the terms of the Term Sheet, CLM intends to acquire a 100% undivided interest in the Project through an asset purchase transaction whereby LM, as the recorded and beneficial owner of the Project, will transfer to CLM 449 mineral claims, totaling approximately 215 square kilometers, located within the Abitibi region (358 claims), and James Bay region (91 claims) of Québec.

As consideration for the Proposed Transaction, CLM has agreed to pay LM aggregate consideration valued at approximately C$2.75 million, consisting of:

C$687,500 in cash payable on closing; and
C$2,062,500 payable through the issuance of common shares of CLM determined based on the 20-day moving average trading price of CLM shares on the TSX Venture Exchange ("TSXV") from June 4, 2026, with such shares to be issued on closing, subject to and in accordance with applicable securities laws and the rules and policies of the TSXV (the "Consideration Shares").

The Consideration Shares will be subject to applicable statutory hold periods and any escrow provisions required by the TSXV and the definitive agreement between the parties (the "Definitive Agreement"). Additional commercial terms, including any net smelter return royalty provisions, escrow arrangements, and other customary transaction terms, are expected to be finalized in the Definitive Agreement.

The Term Sheet contemplates the following:

LM has granted CLM a legally binding exclusivity period until October 1, 2026 while the Company conducts due diligence and the parties negotiate and finalize the Definitive Agreement;
CLM anticipates financing the Proposed Transaction through a combination of internal resources, strategic financing initiatives, and support from existing shareholders and external financial advisors;
LM has agreed to a binding C$1,687,500 break fee in the event of termination of the Term Sheet by LM, including where LM terminates to accept a superior proposal or otherwise breaches its exclusivity obligations;
LM has agreed to grant CLM a right of first refusal over sales of the Consideration Shares, subject to several conditions; and
in the event of a superior proposal, LM has granted CLM a legally binding right to match, subject to certain conditions.

The parties are targeting execution of the Definitive Agreement respecting the Proposed Transaction by July 19, 2026, subject to completion of due diligence and regulatory approvals.

Management Commentary

Richard Quesnel, CEO of CLM, commented:

"This Term Sheet with LM represents a compelling opportunity for CLM to potentially acquire what we believe to be one of the province's most strategically located lithium assets. The Project is located adjacent to the North American Lithium mine, the largest lithium producer in North America. Readers are cautioned that mineralization on the adjacent or nearby properties, including the North American Lithium mine, is not necessarily indicative of mineralization on the Project.

As we proceed with the updated preliminary economic assessment report (the "PEA") for the Kwyjibo Rare Earth Project, in parallel, we continue to evaluate opportunities to strengthen CLM's broader critical minerals portfolio in Québec. We believe this potential transaction complements our long-term strategy of advancing high-quality critical mineral assets located in established mining regions with strong infrastructure and development potential."

Kwyjibo Rare Earth Project Update

With respect to the Kwyjibo Rare Earth Project, the Company has made significant progress in enhancing and refining the PEA to address community concerns regarding the project's environmental footprint. The PEA is expected to be completed in mid to late June 2026. The Kwyjibo Rare Earth Project acquisition (the "Acquisition") is more fully described in the Company's press releases dated November 18, 2025, and February 5, 2026, copies of which are available under CLM's profile on SEDAR+ at www.sedarplus.ca.

About the Project

The Project comprises 449 mineral claims covering approximately 215 square kilometers within a region prospective for lithium-bearing pegmatites. To date, LM and historical operators have completed 131 diamond drill holes totaling approximately 19,000 meters and 50 channel samples on the Project. The majority of the drill holes intersected spodumene-bearing pegmatites at various depths from surface of varying thicknesses and grades. Reported intercepts represent drilled core lengths, and true widths have not yet been determined. The Company notes that the reported intercepts include both grade and downhole interval lengths in accordance with standard mineral exploration disclosure practices.

Some of the highlights from these drilling campaigns conducted by LM (formerly FE Battery Metals and First Energy Metals) and historical operators include:

Rank

Drill Hole

From (m)

Intercept

Sources (Titles/Dates/Links)

LC23-67

161.5

1.29% Li₂O over 23.0 m

FE Battery Metals Intersects 1.29% Lithium Oxide Over 23 Metres At The Augustus Lithium Property (09/05/2023)

LC21-16

153.0

1.17% Li₂O over 19.0 m

FE Battery Metals Drills 1.17% Lithium Oxide Over 19 Metres At Augustus Lithium Property (04/10/2026)

LC24-96

CINCINNATI, June 08, 2026 (GLOBE NEWSWIRE) -- Roto-Rooter Services Company, a wholly owned subsidiary of Chemed Corporation ("Chemed") (NYSE:CHE) announced it has acquired a formerly independent Roto-Rooter franchise serving 21 counties in south Texas for approximately $12.0 million. The service area includes the cities of Corpus Christi, McAllen, Laredo and Brownsville, Texas.

Listed ...

Full story available on Benzinga.com

SRx Health Solutions Acquires 4.99% of Smartkem, Inc. (NASDAQ: SMTK)

Globe Newswire — Mon, 08 Jun 2026 16:07:43 +0000

NORTH PALM BEACH, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE:SRXH) (the "Company") and EMJ Crypto Technologies ("EMJX"), a digital-asset treasury operating platform with which the Company has entered into a definitive merger agreement, today announced acquiring 4.99% of Smartkem, Inc. (NASDAQ:SMTK), a leader in advanced materials, through a shelf take down. In conjunction with the 4.99% of equity, the Company has also purchased convertible preferred securities through a non-brokered private placement.

Additional Information and Where to Find It
In connection with the proposed transaction between the Company has filed with the SEC a Registration Statement on Form S-4 (the "Registration Statement") to register the common stock to be issued in connection with the proposed transaction. The Registration Statement includes an information statement of the Company and a prospectus of the Company (the "Information Statement/Prospectus"), and each of EMJX and the Company may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement is declared effective, the definitive Information Statement/Prospectus will be sent to the stockholders This is not a substitute ...

Full story available on Benzinga.com

Azuria Water Solutions Announces the Acquisition of RSM Lining Supplies

Globe Newswire — Mon, 08 Jun 2026 14:30:00 +0000

TAMPA, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- Azuria® Water Solutions, a leader in technology-enabled water solutions, today announced the acquisition of RSM Lining Supplies™ (RSM). RSM is a global leader in supplying advanced cured-in-place pipe (CIPP) lining materials, equipment, and services.

Founded in 2003 by Richard Davis, RSM is one of the world's largest global suppliers of cured-in-place pipe. RSM will maintain its headquarters in the United Kingdom and its locations in Sydney and Melbourne, Australia. ...

Full story available on Benzinga.com

Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives

Globe Newswire — Mon, 08 Jun 2026 14:00:00 +0000

KEY HIGHLIGHTS

Cana Laboratories, Cosmos Health's wholly owned subsidiary, acquires international patent application WO2025108566A1 from Cloudpharm P.C.
Patent protection being pursued at national and regional levels across key international markets
Technology supports next-generation pharmaceutical, nutraceutical, OTC, and specialized healthcare product development
Expands nanotechnology investment initiatives, leveraging Cana Laboratories' European GMP-certified manufacturing capabilities
Aligned with the Company's broader strategy of expanding its IP portfolio, strengthening vertical integration, and driving long-term shareholder value

CHICAGO, June 08, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories S.A., has acquired ownership of international patent application WO2025108566A1 from Cloudpharm P.C., and expands its nanotechnology investment initiatives.

Following the transfer, Cana Laboratories has initiated the process of pursuing patent protection at both national and regional levels in key international markets as part of the Company's broader IP strategy.

The patent represents an important addition to Cosmos Health's growing innovation portfolio and reflects the Company's commitment to transforming advanced scientific discoveries into commercially viable healthcare solutions. The underlying technology originated from research activities combining early-stage discovery methodologies with advanced pharmaceutical development approaches.

PATENT & IP DETAILS

FIELD	DETAIL
Patent Application	WO2025108566A1
Transferor	Cloudpharm P.C.
Acquirer	Cana Laboratories S.A. (wholly owned subsidiary of Cosmos Health Inc.)
Filing Status	(NASDAQ:SUNE) stock rose Monday as investors reacted to a definitive merger agreement with solar manufacturer Suniva and a broader rally in technology stocks. The Nasdaq was up almost 2%, supporting risk appetite across the market. SUNation, Suniva Strike Merger Deal SUNation Energy and Suniva on Monday signed a definitive reverse merger agreement that would combine solar manufacturing and installation businesses to create a larger U.S.-focused solar platform. The combined company is expected to operate under the Suniva name while maintaining SUNation’s Nasdaq listing. The deal values pre-merger SUNation shareholders’ equity at about $2.26 per share, representing a roughly 100% premium to the stock’s latest closing price. Merger Aims To Boost Domestic Solar Capacity The companies said ... Full story available on Benzinga.com Factorial Lists on Nasdaq, Bringing Solid-State Batteries From Validation to Scale Globe Newswire — Mon, 08 Jun 2026 13:00:00 +0000 BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Factorial Inc. ("Factorial"), a U.S. developer of solid-state battery technology, announced today that it has completed its previously announced business combination with Cartesian Growth Corporation III, a publicly traded special purpose acquisition company. The combined company will operate as Factorial Energy Inc., and its Series A common stock and warrants are expected to begin trading on the Nasdaq Stock Market ("Nasdaq") under the ticker symbols "FAC" and "FACWW", respectively, on June 8, 2026. The transaction implies an equity value of approximately $1.3 billion and provides more than $100 million in gross proceeds to support continued commercialization of Factorial's next generation batteries for defense & aerospace, hyperscale data centers, and e-mobility. Factorial enters the public markets with a track record few battery companies match – support from the U.S. national security investment community, real world vehicle integrations, expansion into high-performance drones, and progress toward the first U.S. solid-state production program for passenger vehicles. Factorial's capital-light commercialization model, built on joint manufacturing partnerships, is designed for rapid, scalable deployment. "We built Factorial to solve one of the hardest problems in energy – making solid-state real at scale," said Siyu Huang, CEO of Factorial. "The automotive industry is the most demanding proving ground in the world, and we've shown our technology can perform in real cars on real roads. That foundation positions us to scale, providing power to drones, robotics, and next generation energy systems. Listing on Nasdaq gives us the platform to accelerate that work and deliver solid-state technology where it matters most." "The team at Factorial is dedicated not just to powering the next generation of drones, robots, e-mobility and energy storage, but to creating long-term shareholder ... Full story available on Benzinga.com Ingredion To Acquire Tate & Lyle For $5 Billion In All-Cash Deal Akanksha Bakshi — Mon, 08 Jun 2026 12:41:46 +0000 On Monday, Ingredion Inc. (NYSE:INGR) announced a recommended all-cash acquisition of Tate & Lyle PLC valued at about 3.7 billion pounds ($5 billion), expanding its specialty ingredients business. The deal broadens Ingredion’s portfolio in texturants, sugar reduction, and fortification while adding capabilities in multi-ingredient systems and recipe development. It also expands the company’s reach across a wider range of food and beverage applications. Tate & Lyle shareholders will receive 595 pence per share, a roughly 59% premium to the May 13, 2026, closing price, plus certain dividends. Synergies, Financing, and Deal Timeline Ingredion expects the transaction to generate about $130 million in annual cost synergies by 2030 and to be accretive to adjusted EPS in the first full year after closing. One-time integration costs are projected at about $175 million. The deal, which has unanimous board backing from both companies, is expected to close in the second half of 2027, subject to shareholder and regulatory approvals. Ingredion plans to fund the acquisition through existing cash, new debt, and a committed bridge financing facility. The company expects leverage to decline to about 2.5 times net debt-to-adjusted EBITDA within 18 months after closing. Ingredion said it has secured an irrevocable undertaking from Huber Equity Corporation ... Full story available on Benzinga.com DEMIRE: Major shareholders launch structured sale process Globe Newswire — Mon, 08 Jun 2026 11:45:00 +0000 DEMIRE: Major shareholders launch structured sale process Major shareholders AEPF III 15 Sarl ("AEPF"), a fund vehicle managed by Apollo Global Management, and Wecken & Cie. are launching a structured process to sell their approximately 90% stake No plans to sell via the stock exchange Objective: A new anchor investor with financial strength and a strategic contribution Foundation laid through stabilisation, portfolio adjustments and financial measures Langen, 8 June 2026. DEMIRE Deutsche Mittelstand Real Estate AG (ISIN: DE000A0XFSF0) ("DEMIRE" or the "Company) announces that its major shareholders AEPF III 15 Sarl ("AEPF"), a fund vehicle managed by Apollo Global Management, and Wecken & Cie., in alignment with the Company, have initiated a structured process to explore the sale of their combined stake of around 90% in DEMIRE. The Company and the major shareholders are being advised by Rothschild & Co. The process is at an early stage. It is not yet clear whether a transaction will go ahead, or in what form. There are currently no plans to sell via the stock exchange. In recent years, DEMIRE has adjusted its portfolio and implemented measures to secure liquidity and stabilise its financing structure. These included, in particular, property sales as well as operational and financial measures to meet existing obligations, including loans and shareholder loans. These steps form the basis for the company's ... Full story available on Benzinga.com Kneat Enters into Definitive Agreement to be Acquired by Thoma Bravo in an All-Cash Transaction, Valuing Kneat at Approximately C$650 Million Globe Newswire — Mon, 08 Jun 2026 11:37:36 +0000 Kneat Shareholders to Receive C$6.50 Per Share in Cash, a 40% Premium to Kneat's Unaffected Share Price Transaction to accelerate Kneat's leadership in digital validation and quality process automation for life sciences LIMERICK, Ireland, June 08, 2026 (GLOBE NEWSWIRE) -- kneat.com, inc. (TSX:KSI) (OTCQX:KSIOF), ("Kneat" or the "Company"), the global leader in digital validation and quality process automation, is pleased to announce that it has entered into a definitive arrangement agreement (the "Arrangement Agreement") with an affiliate of Thoma Bravo, L.P. ("Thoma Bravo" or the "Purchaser"), the world's largest software-focused investment firm, whereby the Purchaser will acquire all of the issued and outstanding common shares (the "Shares") of the Company, subject to obtaining shareholder and other customary approvals (the "Transaction"). Under the terms of the Arrangement Agreement, holders of the outstanding Shares of the Company (other than any Rollover Shares (as defined below)) will receive C$6.50 cash per share (the "Purchase Price"), representing an aggregate total equity value of approximately C$650 million on a fully diluted, in-the-money, treasury-stock-method basis and inclusive of Rollover Shares. Upon completion of the Transaction, Kneat will become a privately held company. The Purchase Price represents a premium of approximately 40% to the closing price of the Shares on the Toronto Stock Exchange (the "TSX") on May 8, 2026, the last trading day prior to Kneat announcing an ongoing strategic review, and a premium of approximately 20% to the closing price on June 5, 2026, the last trading day prior to the announcement of the Transaction. Kneat's platform is designed to digitize data specifically for integrity and traceability, which is central to validation and compliance in the life sciences sector. For customers, this makes Kneat's platform a critical foundation for the confident deployment of Artificial Intelligence ("AI") across regulated environments. Following the closing of the Transaction, Thoma Bravo intends to accelerate Kneat's pursuit of its mission to enable any regulated company to be confident it is developing, manufacturing, and delivering its products to the highest safety standard. "This Transaction represents the culmination of a comprehensive strategic review process undertaken by the Kneat Board of Directors, which has led to a compelling outcome for our Shareholders," said Carol Leaman, Chair of the special committee of independent directors of Kneat (the "Special Committee") that oversaw the Transaction. "We are pleased to have reached an agreement that provides Shareholders with significant, immediate, and certain value. This Transaction recognizes the strength of Kneat's market position, the quality of its platform, and the long-term value created by the management team and employees." "We are thrilled to partner with Thoma Bravo, who we are confident will help us accelerate our mission and our position as the leader in digital validation and quality process automation for life sciences at an exciting time for the industry," said Eddie Ryan, CEO and co-founder of Kneat. "As we begin to leverage our critical position in validation to enable customers to expand their use of our platform to adjacent areas, having the sector expertise, strategic alignment, and resources of Thoma Bravo behind us will be a powerful catalyst. We are energized by the path we are announcing today which delivers value to all our stakeholders." "In today's increasingly complex regulatory environment, more customers are looking to Kneat to provide them with greater control, efficiency, and real-time visibility across mission-critical compliance workflows," said Adam Solomon, a Partner at Thoma Bravo. "We are confident we can apply our operational expertise and deep experience working with market-leading software companies to accelerate Kneat's growth." "We are thrilled to back Eddie and the team at Kneat as they continue to build on their leadership position in digital validation," said Chandler Gay, a Senior Vice President at Thoma Bravo. "Kneat is an exceptional company that is loved by its customers, and we are proud to be partnering with their team." Transaction Details The Company entered into the Arrangement Agreement based on the unanimous approval of the Company's board of directors (the "Board") and the unanimous recommendation of the Special Committee, that the Transaction is fair from a financial point of view to the holders of the Shares (the "Shareholders") (other than any Rolling Shareholders), and is in the best interests of the Company. The Arrangement Agreement was the result of a comprehensive strategic review and negotiation process that was undertaken at arm's length with the oversight and participation of the Special Committee advised by independent and highly qualified legal and financial advisors. See "Unanimous Board Approval" below. Thoma Bravo and certain existing director and management shareholders of Kneat ("Rolling Shareholders") may elect for such Rolling Shareholders to roll a portion of their equity into shares of the Purchaser or an affiliate of the Purchaser, however the terms of any such rollover (including which Shareholders may be Rolling Shareholders or how many Shares may be rolled over) have not been negotiated at this time. Any shares rolled over (the "Rollover Shares") would be at a value equal to the Purchase Price. Any Shares owned by the Rolling Shareholders that are not Rollover Shares will be sold to Thoma Bravo at the Purchase Price. Unanimous Board Approval The Board unanimously approved the Arrangement Agreement following receipt of the unanimous recommendation of the Special Committee. The Special Committee was appointed by the Board to, among other matters, review strategic alternatives for the Company including the Transaction, consider the Company's best interests and the implications to Shareholders and other stakeholders, oversee the evaluation and negotiation of the transaction proposals and provide the Board with advice and recommendations with respect to the Transaction. As such, the Board unanimously recommends that Shareholders vote in favour of the Transaction. The Company intends to hold a special meeting of Shareholders (the "Shareholders' Meeting") by early August 2026, at which the Transaction will be considered and voted upon by Shareholders of record. In making its determination to unanimously recommend approval of the Transaction to the Board, the Special Committee and, in the Board's determination to approve the Transaction, the Board, ... Full story available on Benzinga.com Standard BioTools and Treeline Biosciences Announce Merger Agreement Globe Newswire — Mon, 08 Jun 2026 11:30:00 +0000 Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates Company to be led by Treeline CEO and co-founder Josh Bilenker, MD, and experienced team of proven drug developers Treeline's pipeline includes three Phase 1 programs with multiple anticipated clinical data readouts beginning in 2027 Well capitalized with over $900 million in cash expected at closing, providing runway into 2029 Supplemental investor materials, including management remarks, posted on Standard BioTools website BOSTON, Mass. and WATERTOWN, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools") and Treeline Biosciences, Inc. ("Treeline") today announced they have entered into a definitive merger agreement to combine in an all-stock transaction. Upon completion of the transaction, which is expected to occur in the second half of 2026, the combined company is expected to operate under the name Treeline Biosciences and trade on the Nasdaq under the ticker symbol "TRLN." Since its founding in 2021, Treeline has established a productive in-house discovery and development organization that has brought three programs into Phase 1 development with a fourth planned clinical entry in 2026. These clinical-stage programs address molecular targets in oncology and have expected interim data readouts starting in 2027. Three additional programs are expected to enter the clinic in 2027 and 2028 in oncology, neurology and immunology. The proposed transaction would add approximately $450 million in net cash from Standard BioTools to the combined company's balance sheet. At closing, the combined company is expected to have more than $900 million in pro-forma cash, which is expected to fund operations into 2029. Treeline previously raised approximately $1.2 billion from a syndicate of leading life sciences investors. "2027 and 2028 should be transformative years for Treeline, with interim data expected from our clinical programs and several new programs beginning clinical testing," said Josh Bilenker, MD, co-founder and Chief Executive Officer of Treeline. "After just five years of company operations, today's announcement reflects the productivity and talents of our team. Operating as a public company with a strengthened balance sheet will help us build an enduring biopharma company." "Over the last several months, our Board and management team conducted a comprehensive review of potential growth initiatives and determined that a combination with Treeline is the best path forward to maximize value for our shareholders," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "Standard BioTools was founded with a purpose to accelerate breakthroughs in human health and help develop better drugs faster. Through disciplined execution, we have strategically transformed our portfolio, meaningfully improved our financial profile and strengthened our balance sheet. Treeline has assembled an exceptional team with a proven track record in drug development and built a diversified portfolio of precision medicines focused on some of the most important opportunities in oncology and beyond. Deploying our capital behind this team and pipeline gives our stockholders exposure to a catalyst-rich portfolio with significant potential for value creation in both the near- and long-term." Treeline's Lead Programs and Pipeline Treeline's pipeline includes small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates (TT-ADCs). The unique demands of each target determine which drug modality is used. Treeline currently has three programs in Phase 1 clinical trials. Each was selected based on a robust data package that informed a clear development plan. Additional details regarding Treeline's lead programs and pipeline can be found in the supplemental investor materials posted on the Investor Relations page of Standard BioTools's website. TLN-121 is an oral protein degrader designed to remove BCL6 from cancer cells while avoiding off-targets that could cause toxicity. This profile maximizes its potential for single-agent activity, while maintaining the ability to combine well with standard-of-care lymphoma therapies. In an ongoing Phase 1 study, there is early clinical evidence of broad single-agent activity and tolerability in heavily pretreated B-cell and T-cell lymphoma patients. TLN-372 is an oral inhibitor of KRAS. KRAS mutations are present in roughly one in four adult cancers, including lung, pancreatic, colorectal and gynecological cancers. Through novel chemistry, TLN-372 was designed to achieve deep and sustained pan-KRAS inhibition, while sparing HRAS and NRAS. This profile was chosen because avoiding HRAS and NRAS mediated toxicities could improve its potential to combine with chemotherapy, immunotherapy, anti-EGFR antibodies and other modalities, while preserving dose intensity, in early lines of therapy. In an ongoing Phase 1 study, free drug exposures are consistent with preclinical predictions. As such, the program is on track to demonstrate the therapeutic potential of pan-KRAS inhibition which is not pharmacologically limited. TLN-254 is an oral inhibitor of EZH2, which regulates gene expression and is frequently overactive or mutated in cancer. TLN-254 was in-licensed following Phase 2 evaluation in China, where it was subsequently approved for commercial sale. The program was selected based on its combination potential with TLN-121 for the treatment of aggressive lymphomas. In a Treeline conducted Phase 1 study, single-agent activity and safety have been consistent with published data from China in heavily pretreated T-cell lymphoma patients. A fourth program, TLN-499, is expected to enter Phase 1 in 2026. TLN-499 is an oral protein degrader that selectively targets BCL-XL. Certain cancer cells rely on BCL-XL and other pro-survival proteins to prevent apoptosis, suggesting that antagonizing BCL-XL could meaningfully enhance the activity of other drug classes such as chemotherapy and targeted agents. Treeline also has a robust discovery pipeline spanning oncology, neurology and immunology that is expected to produce three additional expected clinical entries in 2027 and 2028. Treeline plans to provide additional guidance on these programs and the existing clinical portfolio ... Full story available on Benzinga.com Ten10 and The Scale Factory Unite to Form Scale Factory, a UK AI Enablement Consultancy Globe Newswire — Mon, 08 Jun 2026 11:19:27 +0000 LONDON, June 08, 2026 (GLOBE NEWSWIRE) -- Ten10 Solutions and The Scale Factory today announce they have joined together as Scale Factory, an AI enablement consultancy. The combined business covers quality engineering, cloud, data, agentic automation, and next-generation capability, delivered entirely on-shore by UK-based teams. "Fearlessness isn't reckless, it's earned. At Scale Factory, we believe it comes from engineering rigour, honest client relationships, and foundations built to last, not just to launch. When the groundwork is solid, organisations can move faster, take smarter risks, and pursue transformation that actually sticks." Said Chris Thompson, Chief Delivery Officer, Scale Factory The business is built around the organisations that carry the heaviest consequences for getting technology wrong: regulated industries, risk-sensitive environments, and companies with serious AI ambitions. Scale Factory works close to its clients' realities, asks the questions that others sidestep, and judges its own performance by client outcomes rather than project milestones. "This has been a journey that's been years in the making and today feels like the moment it all comes together. Scale Factory isn't just a new name, it's a reflection of everything both businesses have built, and a statement of intent about where we're going. Our clients will notice the expanded capability. What they won't notice is any disruption, because the people, the standards and the relationships they rely ... Full story available on Benzinga.com SUNation Energy and Suniva Enter Definitive Merger Agreement, Creating a Platform for American Solar Manufacturing and Services Leadership Globe Newswire — Mon, 08 Jun 2026 10:50:00 +0000 Combined company to accelerate Suniva's U.S. solar cell manufacturing expansion and market leadership, backed by SUNation's established market presence, deep end-market relationships, and Nasdaq-listed platform Suniva to merge with SUNation, combined company expected to operate under the Suniva name and continue SUNation's Nasdaq listing Transaction expected to enhance domestic solar capacity, support margin expansion and broaden access to U.S. capital markets to fund future growth and strategic opportunities RONKONKOMA, N.Y. and NORCROSS, Ga., June 08, 2026 (GLOBE NEWSWIRE) -- SUNation Energy, Inc. (Nasdaq: SUNE) ("SUNation"), a leading provider of residential and commercial solar energy systems, battery storage solutions, and comprehensive energy services, and Suniva, ("Suniva") the largest and oldest U.S. merchant manufacturer of high-efficiency monocrystalline silicon solar cells, have signed a definitive reverse merger agreement (the "Merger Agreement") pursuant to which Suniva will merge with a wholly-owned subsidiary of SUNation, and the combined company is expected to operate under the Suniva name and continue SUNation's listing on the Nasdaq Capital Market. Pursuant to the Merger Agreement, upon closing, pre-merger SUNation stockholders are expected to own equity with an implied value of approximately $2.26 per share. The transaction represents a premium of approximately 100% over SUNE's most recent closing price. By combining with SUNation's established downstream business in high-electricity-cost markets, Suniva, the country's only U.S.-owned and operated merchant solar cell manufacturer, stands to gain additional market presence and access to U.S. capital markets to fund continued growth in American solar manufacturing. With a successful 1 GW nameplate cell facility operating in Georgia, Suniva is expanding capacity by 4.5 GW in Laurens County, South Carolina, supported by expected financing that is targeted to close later this month. "We've spent the last two years transforming SUNation into a stronger, more disciplined and more resilient platform, and this proposed merger with Suniva is the next logical step in that journey," said Scott Maskin, Chief Executive Officer of SUNation. "By bringing together Suniva's U.S.-based solar cell manufacturing footprint with our high-growth residential, commercial and service businesses in some of the highest electricity-cost markets in the country, we believe we can deliver a unique domestic content offering for customers. SUNation's residential and commercial capabilities, along with deep relationships with other leading installers across the country, should support Suniva and its module partners in accelerating American solar's transition to a domestic supply chain." Tony Etnyre, Chief Executive Officer of Suniva, commented: "Suniva was built on the belief that America's energy future must be built here at home. As the first company to bring U.S. solar cell manufacturing back online, we believe we've proven the manufacturing model works - in metro Atlanta, and soon in Laurens, South Carolina. Along the way, we have learned from some of the best firms in the industry to develop American operating expertise in the highest-barrier layer of the domestic supply chain, the solar cell, and accelerate a productivity migration of solar manufacturing to the U.S. What we believe this combination gives us is the platform to execute our mission at the speed and scale the moment demands. Access to U.S. public capital markets means we can move faster, invest deeper, and expand further into the domestic manufacturing capacity this country urgently needs. SUNation brings an established, customer-facing business that strengthens our foundation as we build toward that future together." TRANSACTION OVERVIEW The transaction, approved by both companies' boards and targeted to close in the second half of 2026, is contingent on stockholder approvals of the issuance of SUNation shares to Suniva stockholders and other items, SEC effectiveness of a Form S-4 registration statement, Nasdaq listing clearance and other customary closing conditions. The transaction combines Suniva's U.S.-based solar cell manufacturing capabilities with SUNation's established downstream installation, service and energy solutions businesses. By pairing Suniva's domestic advanced manufacturing platform and domestic moduling relationships with SUNation's local-market presence, the combined company aims to strengthen domestic supply-chain resilience and expand access to domestically produced solar solutions. Management believes this structure will enhance domestic supply-chain control, support margin expansions over time, and broaden access to U.S. capital markets for growth. Under the Merger Agreement, SUNation Merger Sub, Inc., a wholly-owned subsidiary of SUNation, will merge with and into Suniva, with Suniva surviving and continuing as a wholly-owned subsidiary of SUNation. SUNation is expected to change its name to Suniva, and the combined company is expected to operate under the Suniva name following closing. Based on the merger consideration formula in the Merger Agreement, pre‑merger Suniva stockholders are expected to own approximately 98.2% of the combined company and pre‑merger SUNation stockholders approximately 1.8% upon closing, subject to possible adjustment for SUNation's net cash at closing. COMBINED COMPANY POSITIONING The combined company is expected to operate as a Nasdaq-listed solar platform anchored by Suniva's American-owned and operated manufacturing capabilities alongside SUNation's proven installation and service businesses in high-demand regional markets. SUNation's leadership brings deep relationships across the U.S. residential and commercial solar landscape, and is anticipated to help Suniva and its moduling partners serve these markets with domestic-content cells. The U.S. has roughly 59 gigawatts of solar module-assembly capacity but only about 3 gigawatts of operational cell capacity, leaving module makers heavily reliant on imported cells. Suniva intends to become the leading domestic solar cell supplier serving a more than 500 gigawatt market over the next decade. This combined company structure is designed to align with U.S. industrial and clean energy policy priorities, leverage domestic manufacturing incentives and support continued expansion of American-made solar capacity with the nation's growing energy needs. SUNIVA'S LEADERSHIP POSITION IN THE MERGED COMPANY Suniva brings the one capability ... Full story available on Benzinga.com Red White & Bloom Brands' Subsidiary, Emblem Cannabis Corporation, Completes Acquisition of Ayurcann's Health Canada-Licensed Manufacturing Operations, Leading Vape & Pre-Roll Brands, and Expanded National Distribution Capabilities Globe Newswire — Mon, 08 Jun 2026 10:30:00 +0000 TORONTO, June 08, 2026 (GLOBE NEWSWIRE) -- Red White & Bloom Brands Inc. (CSE:RWB) ("RWB" or the "Company") is pleased to announce that, in connection with the insolvency proceedings of Ayurcann Inc. ("Ayurcann") and its parent, Ayurcann Holdings Corp. (collectively, the "Ayurcann Entities") under the Companies' Creditors Arrangement Act (the "CCAA Proceedings"), RWB's wholly-owned subsidiary, Emblem Cannabis Corporation ("Emblem"), has successfully closed the previously announced purchase of Ayurcann (the "Transaction"). "The successful completion of this acquisition marks an exciting milestone for Red White & Bloom," said Colby De Zen, President of Red White & Bloom Brands. "We are adding some of Canada's most recognized brands in the vape and pre-roll categories, a talented team, and a highly complementary operating platform that strengthens our position in one of the world's most competitive cannabis markets. We believe this transaction delivers immediate value through increased revenue and EBITDA, while also creating a powerful foundation for future growth. As we continue to expand our footprint across North America and other legal cannabis markets, we see significant opportunities to leverage the strength of the Ayurcann brands across a much broader platform. We are excited about what this means for our customers, our team and our shareholders." With the completion of the transaction, Red White & Bloom has expanded its Canadian operating platform through the acquisition of a scaled and fully integrated cannabis manufacturing and brand portfolio. The acquired business includes the nationally recognized Fuego, Xplor and Happy & Stoned brands, together with an active portfolio of more than 90 SKUs distributed through approximately 2,500 retail locations across Canada, primarily within the high growth vape and pre-roll categories. The acquisition also includes a Health Canada-licensed formulation, manufacturing and packaging facility in Pickering, Ontario, operational inventory and equipment, established customer and supplier relationships, distribution arrangements spanning eight provinces and territories, and all licences required to continue operating the business. The acquisition represents a significant milestone in Red White & Bloom's strategy to build a leading vertically integrated cannabis company with operations spanning Canada and the United States. Management expects the transaction to be immediately accretive to both revenue and EBITDA while enhancing the Company's scale, manufacturing capabilities, product breadth and national distribution footprint. In addition, the combination is expected to generate operational synergies across cultivation, procurement, manufacturing, logistics and administration, while supporting continued product innovation and new product development. Importantly, the acquisition adds a ... Full story available on Benzinga.com Zacatecas Silver Enters into Definitive Option Agreement to Acquire Multi-Asset Exploration Portfolio from Heliostar Metals Globe Newswire — Mon, 08 Jun 2026 10:30:00 +0000 VANCOUVER, British Columbia, June 08, 2026 (GLOBE NEWSWIRE) -- Zacatecas Silver Corp. ("Zacatecas Silver" or the "Company") is pleased to announce that it, through its subsidiary Desarrollos Mineros Zacatecas Silver, S.A. de C.V., has entered into a definitive option agreement (the "Definitive Agreement") with Heliodor Metals, S.A. de C.V. and Minera Aurea, S.A. de C.V., being subsidiaries of Heliostar Metals Ltd., (collectively, "Heliostar") to acquire a 100 percent interest in the Cumaro, La Lola, Oso Negro and Ejutla exploration properties located in Sonora, and Oaxaca, Mexico (collectively, the "Exploration Portfolio"). Highlights Acquisition of high-grade, multi-asset exploration portfolio from Heliostar Metals, significantly expanding Zacatecas Silver's Mexican growth platform across premier mining jurisdictions in Sonora and Oaxaca. Oso Negro represents a compelling, undrilled high-grade discovery opportunity, with high-grade gold and silver across multiple multi-metre vein systems with strong depth potential. Cumaro strategically positioned along strike from Coeur Mining's active El Picacho development, hosting extensions of proven low-sulphidation epithermal vein systems within a rapidly advancing district. La Lola provides district-scale exposure (1,183 hectares) anchored by a 5 km vein system up to 40 metres wide. Ejutla adds a substantial 10,603-hectare land position near the San Jose Mine, formerly owned by Fortuna Mines, hosting multiple high-level epithermal veins and potential Carlin-style mineralisation, with strong historical indications of gold-silver mineralization and extremely anomalous pathfinder elements. Transaction Terms Under the terms of the Definitive Agreement, Zacatecas Silver has optioned a 100% interest in the Exploration Properties from Heliostar. In order to exercise the option, Zacatecas Silver will be required to: pay US $450,000 to Heliostar as follows: (i) US $150,000 on the date of execution of the Definitive Agreement (the "Effective Date") (of which US $129,000 has been paid); (ii) US $100,000 on the first anniversary of the Effective Date; (iii) US $100,000 on the second anniversary of the Effective Date; and (iv) US $100,000 on the third anniversary of the Effective Date; issue US $750,000 common shares of the Company (the "Consideration Shares") to Heliostar as follows: (i) US $300,000 of Consideration Shares on the Effective Date (of which 4,217,845 Consideration Shares at a price of $0.085 for total value of US $258,000); (ii) US $150,000 of Consideration Shares on the first anniversary of the Effective Date; (iii) US $150,000 of Consideration Shares on the second anniversary of the Effective Date; and (iv) US $150,000 of Consideration Shares on the third anniversary of the Effective Date. A portion of the consideration, being 14%, will be deferred until certain mineral concessions have been duly registered. The registration of these concessions is pending due to delays in the Mexican government's administrative processing, and is outside of Heliostar's control. The parties anticipate the registration will be completed in due course and the full consideration will ultimately be delivered to Heliostar. The Consideration Shares under (b)(ii), (iii) and (iv) will be issued at the greater of the Market Price and the ten-day volume weighted average price immediately prior to the applicable share issuance. All Consideration Shares will be subject to restrictions on resale for a period of four months from the date of issue. The total number of Consideration Shares will be limited to 12,500,000 Consideration Shares (the "Share Cap"). If the value of the Share Cap is less than the total dollar amount under (b), Zacatecas Silver will pay, in cash, the difference between the amounts. Upon exercise of the option, Zacatecas Silver will grant a 2% net smelter return royalty on the Exploration Properties, of which 50% of the royalty may be purchased, at any time before commercial production, with a one-time payment of US $2,000,000. Three mining concessions are currently subject to the following underlying royalties: (i) the La Barra mining concession is subject to a 1% net smelter royalty, which may be purchased with a one time payment of US $500,000, (ii) the Edaena mining concession is subject to a 1% net smelter return royalty, which may be purchased with a one-time payment of US $250,000, (iii) the Cumaro mining concession is subject to a 1% net smelter return royalty, of which 50% may be purchased with a one-time payment of US $1,000,000. If Zacatecas Silver completes a change of control prior to the exercise of the option, all of the above noted share issuances and cash payments will be due immediately to Heliostar. In addition, if Zacatecas Silver disposes of the Cumaro mineral concession in certain circumstances, Zacatecas Silver will be required to pay to Heliostar: (i) if the disposition occurs during the first two years after the Effective Date, 50% of the value received from such disposition; and (ii) if the disposition occurs from two years to four years after the Effective Date, 25% of the value received from such disposition. Property Overview* Oso Negro (Sonora, Mexico) Oso Negro is a high-priority, undrilled exploration opportunity located within a historic mining district characterized by high-grade precious metal mineralization. Heliostar's previous channel sampling program included 5.15 g/t Au and 953 g/t Ag over 1.2m, 2.55 g/t Au and 346 g/t Ag over 1.8m and a grab sample of 13.3 g/t Au and 534 g/t Ag over 0.6m (see news release dated June 3, 2021 of Heliostar), demonstrating a robust mineralizing system. Significantly, grades are relatively consistent along the strike of the various veins. The project hosts at least four principal veins with average widths of approximately 3 metres and a number of subsidiary veins, including the El Sahuaro, El Prospecto, Santa Rosa, Del ... Full story available on Benzinga.com

M&A

Consolidated Lithium Metals Signs Term Sheet with Linear Minerals to Acquire the Augustus Lithium Project and Additional Lithium Claims in the Abitibi and James Bay Regions of Québec

SRx Health Solutions Acquires 4.99% of Smartkem, Inc. (NASDAQ: SMTK)

Azuria Water Solutions Announces the Acquisition of RSM Lining Supplies

Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives

SUNation, Suniva Strike Merger Deal

Merger Aims To Boost Domestic Solar Capacity

Factorial Lists on Nasdaq, Bringing Solid-State Batteries From Validation to Scale

Ingredion To Acquire Tate & Lyle For $5 Billion In All-Cash Deal

Synergies, Financing, and Deal Timeline

DEMIRE: Major shareholders launch structured sale process

Kneat Enters into Definitive Agreement to be Acquired by Thoma Bravo in an All-Cash Transaction, Valuing Kneat at Approximately C$650 Million

Standard BioTools and Treeline Biosciences Announce Merger Agreement

Ten10 and The Scale Factory Unite to Form Scale Factory, a UK AI Enablement Consultancy

SUNation Energy and Suniva Enter Definitive Merger Agreement, Creating a Platform for American Solar Manufacturing and Services Leadership

Red White & Bloom Brands' Subsidiary, Emblem Cannabis Corporation, Completes Acquisition of Ayurcann's Health Canada-Licensed Manufacturing Operations, Leading Vape & Pre-Roll Brands, and Expanded National Distribution Capabilities

Zacatecas Silver Enters into Definitive Option Agreement to Acquire Multi-Asset Exploration Portfolio from Heliostar Metals